Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products

被引:45
作者
Chandra, S
Groener, A
Feldman, F
机构
[1] Aventis Behring, King Of Prussia, PA USA
[2] Aventis Behring GmbH, Marburg, Germany
关键词
D O I
10.1016/S0049-3848(02)00044-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An issue of great importance and continuing concern with regard to all products derived from human plasma is their safety from potential contaminants in the source material from which they are purified. Since viral contaminants are a major safety consideration with these products, a number of different methods, including dry heating, vapor heating, filtration and nanofiltration, ultraviolet and gamma irradiation, pasteurization, solvent/detergent (S/D) treatment, sodium thiocyanate treatment, and chromatography (immunoaffinity, metal chelation, affinity, and ion exchange), have been developed to remove or inactivate potentially contaminating viruses. Pasteurization and S/D treatment have emerged as the dominant viral inactivation methods. Results summarized in this review demonstrate that pasteurization is the broadest.. and most rigorous currently available method for removal of potential viral contaminants from plasma-derived products. S/D treatment requires control over a large number of manufacturing parameters and has no ability to inactivate nonlipid-enveloped viruses. Pasteurization requires control over only a small number of manufacturing variables, is easily monitored, and remains effective even if deviations are encountered from specified protein and stabilizer concentrations and temperature. In addition, pasteurization is effective against a wide range of lipid-and nonlipid-enveloped viruses. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:391 / 400
页数:10
相关论文
共 57 条
[1]   Genomic screening for blood-borne viruses in transfusion settings [J].
Allain, JP .
CLINICAL AND LABORATORY HAEMATOLOGY, 2000, 22 (01) :1-10
[2]   HUMAN PARVOVIRUS-B19 INFECTION IN HEMOPHILIACS 1ST INFUSED WITH 2 HIGH-PURITY, VIRALLY ATTENUATED FACTOR-VIII CONCENTRATES [J].
AZZI, A ;
CIAPPI, S ;
ZAKVRZEWSKA, K ;
MORFINI, M ;
MARIANI, G ;
MANNUCCI, PM .
AMERICAN JOURNAL OF HEMATOLOGY, 1992, 39 (03) :228-230
[3]  
Benjamin R, 2000, BLOOD, V96, p58A
[4]  
BHATTACHARYYA SP, 2000, HAEMOPHILIA, V6, P343
[5]  
Brandwein H, 2000, Dev Biol (Basel), V102, P157
[6]   Hepatitis C virus infection associated with administration of intravenous immune globulin - A cohort study [J].
Bresee, JS ;
Mast, EE ;
Coleman, FJ ;
Baron, MJ ;
Schonberger, LB ;
Alter, MJ ;
Jonas, MM ;
Yu, MYW ;
Renzi, PM ;
Schneider, LC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19) :1563-1567
[7]  
Brown F, 1999, Dev Biol Stand, V99, P119
[8]   SAFETY ASPECTS IN THE MANUFACTURING OF PLASMA-DERIVED COAGULATION-FACTOR CONCENTRATES [J].
BURNOUF, T .
BIOLOGICALS, 1992, 20 (02) :91-100
[9]   NANOFILTRATION, A NEW SPECIFIC VIRUS ELIMINATION METHOD APPLIED TO HIGH-PURITY FACTOR-IX AND FACTOR-XI CONCENTRATES [J].
BURNOUFRADOSEVICH, M ;
APPOURCHAUX, P ;
HUART, JJ ;
BURNOUF, T .
VOX SANGUINIS, 1994, 67 (02) :132-138
[10]   BIOCHEMICAL AND PHYSICAL-PROPERTIES OF A SOLVENT-DETERGENT-TREATED FIBRIN GLUE [J].
BURNOUFRADOSEVICH, M ;
BURNOUF, T ;
HUART, JJ .
VOX SANGUINIS, 1990, 58 (02) :77-84